Novel monoclonal antibody-based therapies for acute myeloid leukemia

Linde M. Morsink, Roland B. Walter*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

There has been long-standing interest in using monoclonal antibodies to improve outcomes of people with acute myeloid leukemia (AML). While several candidate therapeutics have failed at various stages of clinical testing, improved survival of some patients receiving the CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that monoclonal antibodies have a role in the armamentarium against AML. Over the last several years, work to improve the success of monoclonal antibody-based therapies in AML has focused on the identification and exploration of new antigen targets as much as on the development of novel treatment formats such as use of unconjugated engineered monoclonal antibodies and conjugated antibodies, delivering highly potent small molecule drugs or radionuclides to AML cells. Here, we will provide a brief overview of current efforts with such investigational monoclonal antibody-based therapeutics.

Original languageEnglish
Pages (from-to)116-126
Number of pages11
JournalBest practice & research clinical haematology
Volume32
Issue number2
DOIs
Publication statusPublished - Jun-2019

Keywords

  • Acute myeloid leukemia (AML)
  • Monoclonal antibody
  • Antibody-drug conjugate
  • (radio)immunotherapy
  • Immunotoxin
  • GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS
  • LECTIN-LIKE MOLECULE-1
  • PHASE-I TRIAL
  • MARROW-TRANSPLANTATION
  • THERAPEUTIC TARGET
  • STEM-CELLS
  • PARTICLE IMMUNOTHERAPY
  • VADASTUXIMAB TALIRINE
  • MYELOGENOUS LEUKEMIA
  • CHEMOKINE RECEPTOR

Cite this